Latest 10-Q quarterly reports

Edgewise Therapeutics reported a wider net loss for Q1 2026 compared to the prior year, driven by increased research and development expenses.

Acadian Asset Management Inc. announced a significant increase in revenue and assets under management for the first quarter of 2026, driven by robust client inflows and positive market performance.

Kenvue Inc. reported increased net sales and operating income for the first quarter of 2026, driven by growth across its segments, while continuing preparations for its merger with Kimberly-Clark.

Lantheus Holdings reported a 1.2% increase in revenue for the first quarter of 2026, driven by strong performance in Neuraceq and DEFINITY, despite a decrease in PYLARIFY sales.

PSQ Holdings, Inc. reported its first quarter 2026 financial results, highlighting significant revenue growth in its Financial Technology segment while continuing its strategic divestiture of non-core businesses.

ImmunityBio, Inc. has filed its 2025 Equity Incentive Plan, detailing provisions for stock options, restricted stock units, and performance awards to attract and retain key personnel.

TerrAscend Corp. reported Q1 2026 results with a slight revenue increase, while managing operational exits and anticipating potential tax relief from cannabis rescheduling.

Collegium Pharmaceutical reported a 9% increase in Q1 2026 revenue to $193.5 million, driven by strong performance in Jornay PM and Xtampza ER, while nearing the completion of its AZSTARYS acquisition.

Zura Bio reports a significant increase in R&D expenses for Q1 2026, driven by ongoing clinical trials, while maintaining a robust cash position following a recent equity offering.

WhiteHorse Finance, Inc. reported a net decrease in net assets of $0.687 million for the first quarter of 2026, compared to a net increase of $4.264 million in the prior year period.

Advanced Flower Capital Inc. reports increased net assets and investment income in Q1 2026, driven by a strategic shift to a BDC structure and diversified lending.

NCR Voyix Corporation reported first quarter 2026 results with total revenue of $606 million, a 1% decrease year-over-year, while recurring revenue saw a 4% increase.

Monte Rosa Therapeutics reported a significant decrease in collaboration revenue and an increase in operating expenses for Q1 2026, leading to a net loss, while also highlighting substantial cash reserves and ongoing strategic partnerships.

Vital Farms reports a 15% increase in Q1 2026 revenue to $187.2 million, driven by volume, but net income fell to a loss of $1.5 million due to increased costs and unfavorable sales mix.

Climb Bio, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a net loss of $13.7 million and a cash balance of $146.3 million, while advancing its key drug candidates.

Rapport Therapeutics announces Q1 2026 results, highlighting $20 million collaboration revenue and progress in clinical trials for RAP-219.

Akebia Therapeutics reported a decrease in net product revenue for the first quarter of 2026, primarily driven by lower Auryxia sales, partially offset by increased Vafseo revenue.

Beam Therapeutics reports a significant increase in license and collaboration revenue in Q1 2026, alongside a reduction in net loss, driven by milestone achievements and strategic financing.

Black Diamond Therapeutics reports a net loss of $9.0 million for Q1 2026, with cash reserves projected to fund operations into the second half of 2028.

MarketWise, Inc. reported a net loss of $0.6 million for Q1 2026, with total net revenue decreasing 7.8% year-over-year to $77.0 million, while total billings increased 15.5% to $81.4 million.

Scholar Rock Holding Corporation filed its Q1 2026 Form 10-Q, detailing a net loss of $105.5 million and a significant increase in G&A expenses, while also announcing the resubmission of its apitegromab BLA with a new PDUFA date.

Entrada Therapeutics announced its first-quarter 2026 financial results, highlighting progress in its Duchenne Muscular Dystrophy (DMD) programs and its collaboration with Vertex Pharmaceuticals.

Commerce.com, Inc. announced its first quarter 2026 financial results, showing revenue growth and improved net income compared to the prior year period.

AAON, Inc. reported a significant 54.3% increase in net sales for the first quarter of 2026, driven by robust demand for its BASX-branded data center cooling solutions.

Unity Software Inc. reported its first quarter 2026 financial results, detailing revenue growth driven by Grow Solutions, significant impairment charges, and a strategic focus on core offerings.

Myers Industries reported a 1.8% increase in net sales for Q1 2026, driven by higher volumes and favorable currency translation, alongside a significant 12.6% rise in gross profit due to cost productivity and lower material costs.

WW International reported a Q1 2026 net loss of $52 million on revenue of $168.3 million, with a significant decline in Behavioral Subscription Revenue offset by growth in its Clinical business.

Cullinan Therapeutics reports Q1 2026 results, with a net loss of $49.7 million and cash reserves projected to fund operations for at least 12 months.

Korro Bio, Inc. filed its Q1 2026 Form 10-Q, detailing a net loss of $19.6 million and a cash runway extending into the second half of 2028 following a significant private placement.

Liberty Latin America Ltd. reported flat revenue for the first quarter of 2026, with a net loss attributable to shareholders widening to $22.7 million, impacted by foreign currency fluctuations and increased interest expenses.